AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $127,972,108 | -3.2% | 10,524,022 | 0.0% | 12.11% | +13.4% |
| Q2 2023 | $132,181,716 | +13.3% | 10,524,022 | 0.0% | 10.68% | +10.4% |
| Q1 2023 | $116,711,404 | -8.9% | 10,524,022 | +0.3% | 9.67% | -11.5% |
| Q4 2022 | $128,128,346 | +24.6% | 10,493,722 | +6.6% | 10.92% | +34.4% |
| Q3 2022 | $102,811,000 | -2.8% | 9,847,774 | 0.0% | 8.13% | -11.8% |
| Q2 2022 | $105,765,000 | +12.8% | 9,847,774 | -0.6% | 9.22% | +27.1% |
| Q1 2022 | $93,789,000 | -19.7% | 9,903,761 | -2.1% | 7.25% | -2.9% |
| Q4 2021 | $116,817,000 | +20.9% | 10,114,043 | 0.0% | 7.46% | +28.0% |
| Q3 2021 | $96,589,000 | +0.2% | 10,114,043 | +1.1% | 5.83% | +9.7% |
| Q2 2021 | $96,424,000 | -0.0% | 10,002,443 | +2.5% | 5.31% | -3.3% |
| Q1 2021 | $96,439,000 | -46.9% | 9,761,043 | +24.1% | 5.50% | -42.3% |
| Q4 2020 | $181,652,000 | +63.5% | 7,867,114 | 0.0% | 9.52% | +56.2% |
| Q3 2020 | $111,084,000 | +0.4% | 7,867,114 | +7.3% | 6.10% | -8.2% |
| Q2 2020 | $110,607,000 | +60.7% | 7,334,714 | -1.5% | 6.64% | +15.3% |
| Q1 2020 | $68,816,000 | -4.7% | 7,447,618 | +0.5% | 5.76% | +44.9% |
| Q4 2019 | $72,212,000 | +25.7% | 7,413,920 | +3.5% | 3.98% | +3.9% |
| Q3 2019 | $57,447,000 | -41.0% | 7,162,920 | -8.1% | 3.83% | -19.1% |
| Q2 2019 | $97,298,000 | -6.1% | 7,796,299 | +2.3% | 4.73% | +9.4% |
| Q1 2019 | $103,630,000 | +46.2% | 7,619,833 | +3.0% | 4.32% | +14.5% |
| Q4 2018 | $70,905,000 | -7.9% | 7,401,321 | +16.3% | 3.78% | +21.3% |
| Q3 2018 | $76,967,000 | -20.1% | 6,366,147 | +3.2% | 3.11% | -19.2% |
| Q2 2018 | $96,350,000 | +4.2% | 6,168,347 | +0.3% | 3.85% | -2.6% |
| Q1 2018 | $92,463,000 | +7.0% | 6,147,829 | +2.4% | 3.95% | +6.2% |
| Q4 2017 | $86,427,000 | -22.8% | 6,006,022 | -19.1% | 3.72% | -21.0% |
| Q3 2017 | $111,898,000 | +39.9% | 7,420,288 | -6.6% | 4.71% | +26.3% |
| Q2 2017 | $79,964,000 | +42.3% | 7,940,788 | +0.7% | 3.73% | +40.5% |
| Q1 2017 | $56,206,000 | +76.4% | 7,882,988 | +23.0% | 2.66% | +46.2% |
| Q4 2016 | $31,858,000 | -24.3% | 6,410,030 | +12.7% | 1.82% | -25.7% |
| Q3 2016 | $42,072,000 | +92.2% | 5,685,388 | +41.8% | 2.44% | +47.8% |
| Q2 2016 | $21,891,000 | -27.0% | 4,009,375 | +12.9% | 1.65% | -29.0% |
| Q1 2016 | $30,007,000 | -12.9% | 3,551,173 | 0.0% | 2.33% | +21.5% |
| Q4 2015 | $34,446,000 | +24.7% | 3,551,173 | +79.9% | 1.92% | +44.4% |
| Q3 2015 | $27,622,000 | -1.1% | 1,974,376 | 0.0% | 1.33% | +6.9% |
| Q2 2015 | $27,937,000 | +31.3% | 1,974,376 | +0.9% | 1.24% | +18.1% |
| Q1 2015 | $21,285,000 | +30.8% | 1,956,376 | 0.0% | 1.05% | +10.2% |
| Q4 2014 | $16,277,000 | +39.8% | 1,956,376 | 0.0% | 0.96% | +9.8% |
| Q3 2014 | $11,640,000 | -12.3% | 1,956,376 | -50.7% | 0.87% | -11.9% |
| Q2 2014 | $13,265,000 | -19.3% | 3,971,576 | -50.0% | 0.99% | +45.3% |
| Q1 2014 | $16,442,000 | +74.5% | 7,943,152 | +98.2% | 0.68% | -22.6% |
| Q4 2013 | $9,420,000 | -12.2% | 4,008,576 | -13.3% | 0.88% | -21.8% |
| Q3 2013 | $10,724,000 | -0.4% | 4,622,230 | 0.0% | 1.12% | -11.6% |
| Q2 2013 | $10,770,000 | – | 4,622,230 | – | 1.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |